CME for REMS an education sea change

At a July FDA advisory hearing on ways to increase the safety of extended-release and long-acting opioid drugs, the agency opened the door to using continuing medical education (CME) to help reach the goal.

Dr. Bob Rappaport, director of FDA's division of anesthetic and analgesic products, while reviewing elements of a REMS (risk evaluation and mitigation strategy) for this category, said the FDA would be responsible for approving the content of prescriber training developed by sponsors.

That comment marked “a real milestone,” said Dr. Murray Kopelow, chief executive of the Accreditation Council for CME. “If control of the content remains in the hands of organizations outside of industry, then it's independent and accredited CME can deliver it.”

It means that professional practice gaps, hypothetically, can be reflected by a commercial supporter in an RFP. Then the education could be created specific to a single product. Kopelow stressed, though, that the initiative has to come from the FDA and the content has to be controlled or approved by the FDA.

The FDA advisory committee rejected the agency's proposed REMS.

Once a class-wide REMS is finalized, it could create more opportunity for those CME providers that understand the rules and regulations, and could also come as welcome news to companies that market long-acting and extended-release opioids.

“We're all looking for ways to effectively educate our prescribers and patients and to make sense of our products,” said Dr. Eric Carter, chief science office for King Pharmaceuticals, marketer of Embeda and Avinza, two forms of extended-release morphine.

According to a government report, substance abuse treatment admissions aged 12 or older involving pain reliever abuse more than quadrupled between 1998 and 2008.
You must be a registered member of MMM to post a comment.
close

Next Article in Features


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.